Myriad Genetics Inc (MYGN.OQ)
6 Dec 2013
|Market Cap (Mil.):||$1,902.48|
|Shares Outstanding (Mil.):||74.75|
Nov 20 - Myriad Genetics Inc : * Announces second hrd collaboration * Says research collaboration with Biomarin that will use Myriad's novel hrd
Oct 1 - Shares of molecular diagnostics company Myriad Genetics Inc jumped 13 percent in morning trading after the company said the proposed cut in Medicare reimbursement rates for one of its tests was the result of a clerical error.
* Sees earnings/shr $1.87-$1.94 for year ending June 2014 vs est $1.86
- Molecular diagnostics company Myriad Genetics Inc reported a fourth-quarter profit that handily beat analysts' estimates, helped by higher sales of its breast and ovarian cancer detection test.
Aug 13 - Molecular diagnostics company Myriad Genetics Inc reported a fourth-quarter profit that handily beat analysts' estimates, helped by higher sales of its breast and ovarian cancer detection test.
* Unanimous ruling is first of its kind for U.S. top court
|Johnson & Johnson (JNJ.N)||$94.09||+1.12|
|Abbott Laboratories (ABT.N)||$37.53||+0.61|
|Bristol-Myers Squibb Co (BMY.N)||$50.68||-0.12|
|Bristol-Myers Squibb Co (BMYMP.PK)||$873.04||+43.25|
|Amgen, Inc. (AMGN.OQ)||$113.92||+0.57|
|Monsanto Company (MON.N)||$111.75||+0.78|
|Merck KGaA (MRCG.DE)||€128.25||-2.25|
|Gilead Sciences, Inc. (GILD.OQ)||$74.03||+0.84|
|Mylan Inc (MYL.OQ)||$44.18||+0.83|
|Allergan, Inc. (AGN.N)||$97.98||+1.48|
Earnings vs. Estimates
Analyst Research Reports
Myriad Genetics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: New Constructs, LLC
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.
Provider: Alpha Street Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.